Granted Patent B2

US 9,193,798 · App. 14/550,561 · Granted Nov 24, 2015

Inventors: Gregory Alan Lazar (Indianapolis, IN); Arthur Chirino (Camarillo, CA); Wei Dang (Pasadena, CA); John Desjarlais (Pasadena, CA); Stephen K. Doberstein (San Francisco, CA); Robert J. Hayes (Radnor, PA); Sher Bahadur Karki (Santa Monica, CA); Omid Vafa (Monrovia, CA)

Assignee: Xencor, Inc.

C07K16/32A61K39/395A61K39/3955A61K39/39566C07K16/00C07K16/22C07K16/2863C07K16/2875C07K16/2887C07K16/2893C07K16/2896C07K16/4291A61K2039/505C07K2317/21C07K2317/24C07K2317/34C07K2317/52C07K2317/72C07K2317/732C07K2317/734C07K2317/76C07K2317/77C07K2319/30

Abstract

Claims (8)

1. A protein comprising an Fc variant of a human parent IgG1 Fc polypeptide, said Fc variant comprising a first amino acid substitution at position 243 and a second amino acid substitution at position 264 in the Fc region of said parent Fc polypeptide, wherein numbering is according to the EU index.

2. The protein of claim 1 , wherein said protein is an Fc fusion.

3. The protein of claim 1 , wherein said protein is an antibody.

4. The protein of claim 3 , wherein said antibody is selected from the group consisting of a human antibody, a humanized antibody, and a monoclonal antibody.

5. The protein of claim 3 , where said antibody comprises an engineered glycoform.

6. The protein of claim 3 , wherein said antibody has specificity for a target antigen selected from the group consisting of CD19, CD20, CD22, CD30, CD33, CD40, CD40L, CD52, Her2/neu, EGFR, EpCAM, MUC1, GD3, CEA, CA 125, IgE, HLA-DR, TNFalpha, MUC18, prostate specific membrane antigen (PMSA) and VEGF.

7. The protein of claim 1 , wherein said protein is an Fc fusion or antibody with specificity for a target antigen Her2/neu.

8. A pharmaceutical composition comprising the protein of claim 1 , further comprising a pharmaceutically acceptable carrier.

Assignments (1)

Continuity (9)